Sales Director | Central Us | Hematology
CurrentDirector of Sales, U.S. Complement Business Unit, Central United States. Leading the Central US Region in Hematology for the launch of the world's first and only approved every 8 week infusion, anti-C5 monoclonal antibody & breakthrough terminal complement inhibitor, for the treatment of patients with the serious, life-threatening blood disease of paroxysmal nocturnal hemoglobinuria (PNH). In addition, responsible for leading the Central U.S. commercial strategy & execution for the world's first two and only C5 terminal complement inhibitors for the life-threatening blood disease, atypical hemolytic uremic syndrome (aHUS). Further responsibilities include managing, recruiting, skill development and Sales Force strategy and execution for the full product portfolio across the Central U.S.